We are proud to announce some of the international leaders in medical research and clinical research joining the conference as international speakers panel at the ProCan Sydney International Conference: Advancing Multi-Omics into the Clinic.

Prof Ruedi Abersold, a leader in Molecular Systems Biology at ETH Zürich. His pioneering work in mass spectrometry-based proteomics has reshaped biological understanding of proteins. Co-founder of the Institute of Molecular Systems Biology and recipient of the Körber European Science Prize, Ruedi continues to innovate at the nexus of biology, chemistry, and computation.

Prof Bernhard Kuster, Professor of Proteomics at Technical University of Munich and Director of the Bavarian Biomolecular Mass Spectrometry Center. His research focuses on personalised cancer therapy through understanding drug impacts on cellular signaling, guiding molecular tumour board decisions. Prof Kuster has co-founded start-ups in proteomics and AI, advancing innovation in these fields.

Dr Chris Whelan, Chair & Co-Founder of the Pharma Proteomics Project. With a neuroscience and multi-omics background, he led the ENIGMA-Epilepsy consortium and held senior R&D roles at multiple pharmaceutical companies. Chris spearheads efforts to generate population-scale proteomic and clinical data through collaboration with 13 biopharmaceutical companies, leveraging 55,000 blood plasma samples from the UK Biobank.

Prof Anna DeFazio is Sydney West Chair in Translational Cancer Research at the University of Sydney, she leads gynaecological cancer research at The Westmead Institute for Medical Research and Westmead Hospital. Prof DeFazio is also Director of the Centre for Cancer Research at WIMR and co-leads the Ovarian Cancer Stream at The Daffodil Centre. Her research on clinico-genomic factors in ovarian cancer treatment is pivotal in advancing that ovarian cancer research. Prof Lois Holloway is a radiation oncology medical physicist at the Ingham Institute Medical Physics and Liverpool and Macarthur Cancer Therapy centres. She leads a multidisciplinary team focused on using imaging data to improve cancer care. Prof Holloway has published over 200 peer-reviewed papers and mentored 20+ PhD candidates. She also established the Australian Cancer Data Network, a groundbreaking initiative using iterative machine learning to transform cancer data analysis across Australia. A/Prof Vanessa (Ness) Tyrrell is Head of the Clinical Translation Research Division and Program Director of the ZERO Childhood Cancer National Precision Medicine Program at Children’s Cancer Institute, Ness is pivotal in shaping a sustainable precision medicine platform for paediatric oncology. With over 30 years of expertise in genetic testing and a leader in her field, Ness’s contributions are transforming research-driven clinical care. Prof Zornitza Stark is a clinical geneticist at Victorian Clinical Genetics Services (VCGS) for Australian Genomics. Prof Stark is dedicated to integrating genomic testing into healthcare, especially for diagnosing rare diseases in children. Since 2014, she’s led key projects with Melbourne Genomics and Australian Genomics, driving advancements in rare disease diagnosis.

Dr Bing Zhang, a Professor at Baylor College of Medicine and CPRIT Scholar, renowned for his groundbreaking work in computational cancer proteogenomics, which earned him the 2023 Gilbert S. Omenn Computational Proteomics Award (US HUPO). With over 180 peer-reviewed papers, Dr Zhang’s research integrates genomic and proteomic data to advance cancer biology and patient outcomes.

Dr Jennifer Van Eyk, PhD, a leading expert in clinical proteomics and the Erika Glazer Endowed Chair in Women’s Heart Health at Cedars-Sinai Medical Center. Dr Van Eyk develops personalised biomarkers and therapies through advanced protein mass spectrometry, leading the Advanced Clinical BioSystems Research Institute and the Precision Biomarker Laboratories.

Prof David Thomas, inaugural Director of the Centre for Molecular Oncology at UNSW and Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research. As CEO of Omico, he leads a national precision medicine program for rare and early-onset cancers. With over 200 research publications, his work focuses on applying genomic technologies to cancer research and management.

We are thrilled to host these remarkable industry leaders and be able to share their insights with many other researchers at this event. If you would like learn more about each of them, please tap here: https://www.procanconference.au/